Akynzeo is a combination medication used to prevent chemotherapy-induced nausea and vomiting (CINV). It contains netupitant and palonosetron [1]. Netupitant is a neurokinin-1 (NK1) receptor antagonist, and palonosetron is a serotonin-5-HT3 receptor antagonist [1][2]. Together, these two drugs work to block different pathways in the body that can trigger nausea and vomiting [2].
What is Akynzeo used for?
Akynzeo is prescribed to prevent both acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy [1]. It is administered as a single oral capsule [3].
How does Akynzeo work to prevent nausea and vomiting?
Chemotherapy can trigger the release of substances like substance P and serotonin, which bind to NK1 and 5-HT3 receptors respectively, leading to nausea and vomiting. Akynzeo's components target these receptors. Netupitant blocks the NK1 receptors, preventing substance P from binding. Palonosetron blocks the 5-HT3 receptors, preventing serotonin from binding. By blocking both pathways, Akynzeo provides a more comprehensive protection against CINV [2][4].
When does Akynzeo's patent exclusivity expire?
Information regarding patent expiry for Akynzeo is available through resources like DrugPatentWatch.com [5]. Patent data suggests various patent statuses and potential expiry dates for the drug and its components, which can influence the availability of generic alternatives.
Who makes Akynzeo?
Akynzeo was developed by Helsinn Healthcare S.A. [1].
How is Akynzeo administered and what is the dosage?
Akynzeo is given as a single oral capsule approximately one hour before the start of chemotherapy [3]. The recommended dose is 300 mg of netupitant and 0.5 mg of palonosetron [1]. It is typically given in combination with a corticosteroid, such as dexamethasone [1][3].